-+ 0.00%
-+ 0.00%
-+ 0.00%

Alzinova outlines Phase 2a trial design for Alzheimer's vaccine ALZ-101

PUBT·11/16/2026 20:15:46
Listen to the news
Alzinova outlines Phase 2a trial design for Alzheimer's vaccine ALZ-101
  • Alzinova is presenting its Phase 2a ADVANCE trial design for Alzheimer’s vaccine ALZ-101 at CTAD in Boston, November 16-19, 2026.
  • The placebo-controlled study will assess whether ALZ-101 slows clinical progression in early Alzheimer’s disease.
  • Enrollment of approximately 120 participants aged 50-85 is scheduled to begin in late December 2026.
  • Completed Phase 1 results showed favorable safety and tolerability, with vaccine-specific immune responses in most participants.
  • An interim analysis, including a futility assessment, is planned for the third quarter of 2028; results are expected in late 2029.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzinova AB published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.